IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The share price may drop further on Thursday like many other small cap shares. What an opportunity to buy more!
Not small fry at all Nick.
I am certain the update will demonstrate further progress towards cashflow breakeven. That in itself is positive.
How the market reacts, of course, will depend entirely on how good that progress is and in particular, whether its enough to finally stave off concerns about a raise.
Hoping for a very positive update as I have just topped-up my ISA account, which together with my SIPP holding takes me to 200k shares. Small beer for some, but a significant investment for me!
Good luck and best wishes to all LTHs
Nick
On the TU, it really is worth listening to this again, particularly from 8.41-9.04 when Yates explains our revenue is weighted to H2 and is aiming for significant H2/H2 growth, and from 15.47 to 17.05 when he talks about cash burn, cost control and specifically says that even with a flat H2 equivalent revenue, “which is absolutely not where we’re going to be” we should see an improvement in cash.
So I’m expecting H2 revenue to at the very least higher than the £2.9m for H2 last year.
https://www.youtube.com/watch?v=4Z32joS9aD4
You did - Folium Science and their CrispR test for testing Salmonella in chicken flocks. So absolutely, it’s not just the home, but in the field and the farm.
And add to that the AMR concern. AMR is just as much fostered in animal populations because of anti biotic misuse as it is in humans, and there’s a real drive for accurate cheap testing methods to address that misuse. Again, great for us.
I post about Yates interest in HN51 not because I want to see another potentially more deadly pandemic, but because much of what can affect humans comes from animals. Currently the biggest HN51 concern is that the world doesn’t know how big the problem is because there’s no effective diagnostic surveillance. That presents an opportunity for us. And god forbid we did see a global rise, well if we had an accurate cheap diagnostic ready to go then our value might see rises like NCYT did with C19.
Precisely Muck. The key words in your post are ". . . huge global . . .".
I genuinely don't want to sound rampy and I certainly wouldn't try to sell myself as some kind of marketing guru but IMO the TAM for 'home' testing is truly immense, it has barley got started, it will impact on every healthcare service in the world and ABDX are in the vanguard.
And not just in the 'home'. Do I recall correctly a topic discussed last year regarding animal testing (was it foot and mouth, BSE? I don't recall exactly) where the Vet, farmer etc could take tests out into the field to test animals and get results in minutes, which could effect delivering treatment or culling a herd. So apart from the more familiar subjects discussed here (pregnancy, hormone, STD's etc testing) let's ponder for a moment the potential for animal testing on a global scale too.
As far as the bottom line is concerned, a test is a test.
Just for info, but this just shows how scientific interest in lateral flow has increased, and the huge variety of potential applications it can be applied to.
6 months into this year there have been more publications than in the whole of 2018. They say war breeds invention - C19 has done the same for LFT awareness and innovation.
https://pubmed.ncbi.nlm.nih.gov/?term=%22Lateral+flow%22&timeline=expanded&sort=date
Only other thing I’d say is that, whilst retail sales and distribution will grow as greater responsibility for healthcare moves to the home and the individual, we can’t forget the potentially huge global centralised healthcare market that great products like those from Loop, Upfront and 52N are targeting.
Well said Apre, and agreed.
As a very small point, when I first stated watching the ABDX LinkedIn feed closely (about 18 months ago), they had about 3400 followers. Now it’s 5655 and rising each month. Still might not seem a lot but that’s a 60% rise and mostly from academia and industry.
Last year the TU was three working days post year end, so I’m quietly hoping Thursday. If not then I’m expecting it next week.
Great stuff, as ever, Muck.
Just by the by, it seems to me that ABDX, having turned the tanker around, are aiming to establish an entire portfolio of products and clients. They are not the one trick pony Covid test outfit that they unfortunately may have been perceived as in the not too distant past. They are emerging as leaders in their field, the 'go-to-guys' in the CDMO world. IMO Abingdon will have a huge brand image among the professionals in their sector.
At some point in the relatively near future, LFT-type tests for a large range of conditions/illnesses etc will be everywhere in society . . . GP's surgeries, high street chemists, next to the chewing gum and batteries by the till in Asda . . . and I feel quite sure that many of them will have at some point passed through ABDX's increasingly capable hands. Yet most people who use them will never know of ABDX. That's fine, they don't need to. They just need the products.
If I had any spare cash I would be adding.
Update this week?
It won’t be a game changer for us in and of itself, but that’s not really what ABDX is all about. We’re about having fingers in a lot of pies. In 12 months time we could easily be manufacturing at scale and at high margin for Upfront, 52 North, Hormona, FOFH, Salignostics (for much wider global distribution), Loop, and plenty of others, not to mention potential widespread adoption of Eco-Flo and growth in our own core CDMO and distribution business.
It might seem a bit dull and boring at the moment but, as I’ve said, I’m struggling to find much downside risk here, am excited by all the potential, and agree we’re cheap as chips.
Great point. Maybe a good few months worth before couples resort to IVF or who simply want to find their optimum time for conception and then there will be more easily accessed information for menopausal women to help with the diagnosis of typical conditions experienced at that time of life. As if Abingdons range of commercial projects couldn't get anymore exciting lol. Sorry I find it hard not to be enthusiastic about ABDX. It's just a matter of time before we see the breakthrough we're waiting on. Fantastic buying price at the moment too.
No problem - the other thing to bear in mind with Hormona is that their tests are for regular hormone monitoring.. Regular means repeat manufacturing.
Wow then. Thanks Muck. I know so many families who would have valued a test like that.
The article embedded in the linkedin post actually says the launch will be in the Autumn.
But that's not too far away.
And interestingly, it also says that most of the current Hormana customers are either in Sweden.......or the US. And it also looks like there are 3 different tests.
I have little doubt that we will be making them but, as is ever the case I think they will need reg approval first and, so far at least, I can't find them anywhere on the MRHA or FDA approved registers. But for Hormona to be signposting a launch indicates approval (if required) shouldn't be far off.
It is difficult to keep track of everyone we are working with. See this article from July last year in which Hormona say
"Hormona is proud to partner with Abingdon Health to further the research and development of its hormone health projects; making full use of Abingdon’s CDMO services from start to finish."
https://www.femtechworld.co.uk/features/why-employers-should-prioritise-womens-health-abi23/
Thanks Muck for the new links posted. Couldn't see the connection of ABDX to Hormona as the Hormona test looks like a real breakthrough. Probably missed it in all your previous messages!
Hormona - posted this morning;
https://www.linkedin.com/posts/hormona_hon-ligger-bakom-nytt-hormontest-f%C3%B6r-kvinnor-activity-7213461174284144640-SWE7?utm_source=share&utm_medium=member_desktop
Interesting to see the coverage they're getting, but also "The article also covers our incredible success so far and our exciting upcoming launch of at-home hormone tests, a major innovation in women’s health."
Been a while coming, but looks like their home tests are about ready to go.
And a little one, but apparently we are now in "Plastic Free July". Would be a great time for an announcement on Eco Flo, which is certainly one of the things on my radar at the mo. See also this
https://www.linkedin.com/posts/york-biotech-campus_sciencepark-bioscience-activity-7213458471453630465-2GjM?utm_source=share&utm_medium=member_desktop
Morning Trader - bit confused by your last because Alta Bioscience isn’t (as far as I’m aware) connected to ABDX, other than it’s owned by Chris Hand.
As we await the update.., its interesting to see what Yates likes and one thing he has consistently reacted to on Linkedin are articles about the rise of HN51 (Bird Flu) and its more recent transmission into humans from animal populations.
So it wasn't surprising to see him react to this from FIND published today, in which they call for urgent investment in LFT diagnostic solutions and comment, in particular, that Nucleic Acid molecular tests (which our PCRD product is custom made to support) are the gold standard.
Now, I suspect Yates might just be reacting because he agrees that someone should get on with developing a specific HN51 LFT (there are currently none commercially according to the article), but there is always the possibility we have one in the pipeline already.
https://www.finddx.org/publications-and-statements/press-release/lack-of-h5n1-influenza-diagnostics-undermines-global-pandemic-readiness/
Another post on LinkedIn by Chris;
Alta Bioscience Ltd is delighted to be sponsoring The Chemistry and Biology of Natural Products Symposium XVII at Warwick University next week on 4th and 5th July. We'll be there with details of our #aminoacid analysis, #protein sequencing and #peptide synthesis services. Details of the symposium are below:
The second part of that post is very interesting as he is updating on the progress of their research and testing
There’s a bit of an oddity I’ve been puzzling over.
As per below, ABDX have said “ Don't miss our very own Dr. Mark Jones' talk (more to come)”
The oddity is that Mark, whilst a Dr (PHD from 20 years ago) is our Chief Operating Officer and an expert in technical transfer and scale up. He’s not our CSO or CTO, being those I would have expected to present at what is essentially a conference about scientific advancements.
We know that the FOFH tests got design freeze in March and that we’d be providing “regulatory and technical transfer CDMO services to Find Out throughout H2-FY24.” That is absolutely work I’d expect Mark to be working on.
So, I’m wondering if the reason Mark is the one speaking is because the FOFH tests are using innovative tech. That would better explain our investment.
Just a musing - ignore as you will!
Maybe 2 years, a couple good full year results...
I’ve been looking at this a bit more.
This is the speaker list, and it’s certainly not small beer stuff. Interesting as well to see us being just one of two premier sponsors for such a US centric conference.
https://www.nextgenerationdx.com/Speaker-Biographies
And it’s not cheap to attend either, at $3,300 per participant for a commercial enterprise buying the full package.
Can’t imagine the sponsorship was cheap either. Yates must feel it’s worth it, and that we can afford it.